Company Overview

Asahi Songwon Colors Limited is a leading manufacturer of blue (Phthalocyanine) pigments for ink, plastics, paint, textile and paper industries. The company has recently ventured into manufacturing yellow and red (AZO) pigments, as well as APIs.

Operational Scale:

  • 4 manufacturing facilities
  • 3 decades of manufacturing expertise
  • Exporting to 19 countries
  • Serving 101 customers
  • Strong technical capabilities
  • Long-standing relations with MNCs

Manufacturing Locations and Products:

  • Padra: Blue pigments
  • Dahej: Red and yellow pigments
  • Odhav: API & API intermediate
  • Chhatral: API & API intermediate

Strategic Business Evolution (2014-2026)

The company has significantly transformed its business model:

  • Production facilities increased from 1 to 4
  • Product portfolio expanded from single product (blue pigments) to multi-product (blue pigments, AZO pigments, API)
  • Customer base grew from 19 to 101+ customers
  • End-use diversification: Revenue from ink industry reduced from >90% to ~55%, with coatings and plastics becoming key focus areas
  • Domestic market share expanded substantially
  • Process water recycling implemented at 80%

Global Footprint

The company exports to 19 countries including USA, Korea, Japan, Spain, Belgium, South Africa, Brazil, China, Italy, Indonesia, Malaysia, Philippines, Singapore, Taiwan, UAE, UK, Vietnam, Bangkok, and Thailand.

Export Contribution: 68% of revenue in H1FY27 (on standalone basis)

Board of Directors

The presentation details the company's board structure:

  • Mrs. Paru M. Jaykrishna: Chairperson & Managing Director
  • Mr. Gokul M Jaykrishna: Managing Director
  • Mr. Arjun G Jaykrishna: Chief Executive Officer & Executive Director
  • Mr. Samveg Lalbhai: Director
  • Mr. Maulik Mehta: Director
  • Mr. Rupesh Shah: Director
  • Mr. Anil Jain: Director
  • Mr. Sanjay Srivastava: Director
  • Mrs. Shivani Revat Lakhia: Director
  • Mr. Mitesh Patel: Executive Director

Business Segments

Phthalocyanine Pigments (Mainstay Business)

  • Backward integrated for Beta and Alpha blue production
  • Long customer approval process creates entry barriers
  • Mature market growing at mid-single-digit rate
  • Sticky customer relationships with high switching costs
  • India now caters to >70% of global phthalocyanine pigment demand
  • One of the largest manufacturers of CPC Blue crude globally

AZO Pigments (Growth Driver)

  • Joint venture with Tennants Textiles Colours Limited (UK)
  • Domestic manufacturing ensures lower production costs
  • Few operational players in the segment
  • Benefiting from China+1 strategy and production shift from China
  • Global organic and specialty pigment market estimated at $5 billion

API Business (Atlas Life Sciences)

  • Acquired remaining 22% stake, now 100% subsidiary
  • Manufacturer of Anti-convulsant, Anti-psychotic and Anti-diabetic APIs
  • Key products include Pergabalin, R-Compound, Levosulpiride, Amisulpride, Glicazide, Phenylephrine, Dapagliflozin, Etoricoxib
  • Market leader in Pregabalin
  • 10 products under R&D including 6 new molecules
  • Odhav plant running at optimum capacity utilization
  • Chhatral site commenced commercial production of API intermediates

Atlas Financials (H1FY27): Revenue: ₹72.09 crore, PBT: ₹2.52 crore, PAT: ₹1.93 crore

Strategic Advantages

  • High lead time for customer approvals creating entry barriers
  • Benefiting from global supply chain realignment away from China
  • Strategic location in chemical cluster providing skilled labor, infrastructure, and raw material proximity
  • Stringent quality control with zero product returns over 3 decades
  • Long-term relationships with marquee clients
  • Sustainability-focused business strategy

Financial Performance Highlights (Consolidated)

Q2FY27 Performance (₹ in Crores)

  • Revenue from Operations: ₹201.36 (66.55% YoY growth from ₹120.90)
  • Other Income: ₹2.18 (31.94% YoY growth from ₹1.65)
  • Total Income: ₹203.54 (66.09% YoY growth from ₹122.55)
  • Total Operating Expenses: ₹176.58 (58.50% YoY growth from ₹111.41)
  • EBITDA: ₹26.96 (141.92% YoY growth from ₹11.14)
  • EBITDA Margins: 13.25% (415 bps improvement from 9.09%)
  • Interest Cost: ₹2.28 (19.82% reduction from ₹2.85)
  • Depreciation: ₹4.67 (0.48% reduction from ₹4.69)
  • PBT: ₹20.01 (454.73% YoY growth from ₹3.61)
  • PAT: ₹14.89 (610.16% YoY growth from ₹2.10)
  • EPS: ₹12.78 (569.11% YoY growth from ₹1.91)

H1FY27 Performance (₹ in Crores)

  • Revenue from Operations: ₹390.27 (44.13% YoY growth from ₹270.78)
  • Other Income: ₹2.97 (4.39% reduction from ₹3.11)
  • Total Income: ₹393.24 (43.58% YoY growth from ₹273.89)
  • Total Operating Expenses: ₹333.68 (33.08% YoY growth from ₹250.74)
  • EBITDA: ₹59.56 (157.29% YoY growth from ₹23.15)
  • EBITDA Margins: 15.15% (669 bps improvement from 8.45%)
  • Interest Cost: ₹4.87 (18.71% reduction from ₹5.99)
  • Depreciation: ₹9.33 (0.04% growth from ₹9.33)
  • PBT: ₹45.36 (479.01% YoY growth from ₹7.83)
  • PAT: ₹33.92 (622.95% YoY growth from ₹4.69)
  • EPS: ₹29.10 (532.61% YoY growth from ₹4.60)

Historical Financial Performance (FY22-FY26)

Profit & Loss (₹ in Crores):

  • Revenue: FY22: ₹410.82, FY23: ₹504.55, FY24: ₹426.24, FY25: ₹562.36, FY26: ₹535.48
  • EBITDA Margins: FY22: 9%, FY23: 2%, FY24: 5%, FY25: 11%, FY26: 10%
  • PAT: FY22: ₹14.65, FY23: (₹18.47), FY24: ₹15.64, FY25: ₹16.86, FY26: ₹17.78

Balance Sheet (₹ in Crores):

  • Total Equity: FY22: ₹284.43, FY23: ₹260.05, FY24: ₹265.95, FY25: ₹282.50, FY26: ₹297.88
  • Total Assets: FY22: ₹469.67, FY23: ₹546.70, FY24: ₹574.74, FY25: ₹589.96, FY26: ₹603.01

Cash Flow (₹ in Crores):

  • Operating Cash Flow: FY22: (₹0.38), FY23: ₹29.97, FY24: ₹8.73, FY25: ₹57.92, FY26: ₹43.24
  • Investing Cash Flow: FY22: (₹28.16), FY23: (₹77.21), FY24: (₹13.14), FY25: (₹5.39), FY26: (₹6.78)
  • Financing Cash Flow: FY22: ₹28.38, FY23: ₹47.49, FY24: ₹4.37, FY25: (₹49.49), FY26: (₹38.00)

Management Commentary

Mr. Arjun G Jaykrishna (CEO & Executive Director)

Q2FY27 was very strong for phthalocyanine pigment business with improvement on every key measure. Margin expansion reflects supply chain strength and sustained cost optimization efforts. Expects to sustain EBITDA margins of 13-15% over longer term. Anticipates Q3 softness due to inventory management but expects significantly better performance than Q3FY26.

Mr. Gokul M Jaykrishna (Managing Director)

Q2 challenging for Azo business with performance below expectations, though sales recovered to earlier levels. Business remains EBITDA-positive and cash-positive. API business growing volumes at 18% annually but subdued by price pressure. Reduced gross borrowings by ₹49 crore during H1, strengthening balance sheet. Evaluating growth opportunities for next phase.

Capital Structure and Debt Management

The company reduced gross borrowings by approximately ₹49 crore during H1FY27, significantly strengthening the balance sheet. Continued deleveraging as debt falls and profitability improves.

Forward Outlook

  • Phthalocyanine business expected to sustain 13-15% EBITDA margins
  • H2FY27 expected to be better than H1FY27 for Azo business
  • API business performance improvement expected as price pressure eases
  • Continued focus on growth opportunities and strategic expansion